The Cost and Financial Burden of Thyroid Cancer on Patients in the US
Authors:
- 1 June 2022
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 148 (6) , 568-575
Abstract
Importance In the US, thyroid cancer has been identified as a cancer type with a high degree of associated financial burden on patients, and survivors of thyroid cancer report higher rates of bankruptcy than those of other cancer types. However, the available literature on the financial burden of thyroid cancer has not yet been described. Observations Estimates of the out-of-pocket costs of initial thyroid cancer diagnosis and treatment range widely ($1425-$17 000) and are influenced by age, surgical treatment type, and health insurance coverage. The rates of patient-reported financial burden are heterogeneous (16%-50%) and are rarely compared with those of other cancer types. Independent risk factors of financial burden have included younger age, lack of health insurance, and annual household income of less than $49 000. Two studies measured medical debt associated with thyroid cancer diagnosis and treatment at notably different rates (2.1% vs 18.7%). The bankruptcy incidence at 1 year after cancer diagnosis is highest for thyroid cancer (9.3 per 1000 person-years) than other studied cancer types (ie, lung, uterine, leukemia/lymphoma, colorectal, melanoma, breast, prostate) and 4.39-fold higher than control individuals among those aged 35 to 49 years. Conclusions and Relevance Current estimates of the financial burden of thyroid cancer are methodologically limited and are based on cross-sectional analyses of patient-reported data. We propose novel frameworks for new research by improvements in (1) data sourcing and utilization, (2) study design, and (3) pilot interventions. To understand how out-of-pocket thyroid cancer-related expenditures transition to various forms of debt, how households finance ongoing costs of care, and rates at which debts are sent to collection agencies, future research should focus on integrating underutilized sources of primary data, including credit reports, public records, and mortgage-backed securities loan-level data. Improvements in study design, such as the development of prospective cohorts, can allow for more objectively measured estimates of out-of-pocket costs, and robust covariate analysis can further reveal the influence of demographic factors, including age, sex, race, income, and health insurance coverage. Finally, new pilot interventions on cost controls can both enable further study and alleviate financial burden.Keywords
This publication has 48 references indexed in Scilit:
- Economic Burden of Cancer Survivorship Among Adults in the United StatesJournal of Clinical Oncology, 2013
- Are survivors who report cancer‐related financial problems more likely to forgo or delay medical care?Cancer, 2013
- The Clinical and Economic Burden of a Sustained Increase in Thyroid Cancer IncidenceCancer Epidemiology, Biomarkers & Prevention, 2013
- Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer DiagnosisHealth Affairs, 2013
- National Estimates of Out-of-Pocket Health Care Expenditure Burdens Among Nonelderly Adults With Cancer: 2001 to 2008Journal of Clinical Oncology, 2011
- Bending the Cost Curve in Cancer CareNew England Journal of Medicine, 2011
- Projections of the Cost of Cancer Care in the United States: 2010-2020JNCI: Journal of the National Cancer Institute, 2011
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Online Access to Court Records - from Documents to Data, Particulars to PatternsSSRN Electronic Journal, 2008
- Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancerThe American Journal of Medicine, 1994